GB2485169A - (R)-flurbiprofen for use in the treatment of multiple sclerosis - Google Patents

(R)-flurbiprofen for use in the treatment of multiple sclerosis Download PDF

Info

Publication number
GB2485169A
GB2485169A GB1018519.7A GB201018519A GB2485169A GB 2485169 A GB2485169 A GB 2485169A GB 201018519 A GB201018519 A GB 201018519A GB 2485169 A GB2485169 A GB 2485169A
Authority
GB
United Kingdom
Prior art keywords
flurbiprofen
treatment
multiple sclerosis
present
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1018519.7A
Other languages
English (en)
Other versions
GB201018519D0 (en
Inventor
Irmgard Tegeder
Gerd Geisslinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goethe University Frankfurt
Original Assignee
Goethe University Frankfurt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goethe University Frankfurt filed Critical Goethe University Frankfurt
Priority to GB1018519.7A priority Critical patent/GB2485169A/en
Publication of GB201018519D0 publication Critical patent/GB201018519D0/en
Priority to JP2013537131A priority patent/JP5903438B2/ja
Priority to KR1020137010891A priority patent/KR101877587B1/ko
Priority to CN2011800529378A priority patent/CN103209692A/zh
Priority to CA2816911A priority patent/CA2816911C/en
Priority to RU2013125470/15A priority patent/RU2595861C2/ru
Priority to US13/881,088 priority patent/US20130309199A1/en
Priority to PCT/EP2011/069319 priority patent/WO2012059541A1/en
Priority to BR112013010883A priority patent/BR112013010883A2/pt
Priority to EP11784967.9A priority patent/EP2635271A1/en
Publication of GB2485169A publication Critical patent/GB2485169A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB1018519.7A 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis Withdrawn GB2485169A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis
EP11784967.9A EP2635271A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)
CA2816911A CA2816911C (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)
KR1020137010891A KR101877587B1 (ko) 2010-11-03 2011-11-03 다발성 경화증(ms)의 새로운 치료
CN2011800529378A CN103209692A (zh) 2010-11-03 2011-11-03 多发性硬化(ms)的新疗法
JP2013537131A JP5903438B2 (ja) 2010-11-03 2011-11-03 多発性硬化症（ｍｓ）の新規の治療
RU2013125470/15A RU2595861C2 (ru) 2010-11-03 2011-11-03 Новое лечение рассеянного склероза ( рс )
US13/881,088 US20130309199A1 (en) 2010-11-03 2011-11-03 Novel Treatment of Multiple Sclerosis (MS)
PCT/EP2011/069319 WO2012059541A1 (en) 2010-11-03 2011-11-03 Novel treatment of multiple sclerosis (ms)
BR112013010883A BR112013010883A2 (pt) 2010-11-03 2011-11-03 tratamento de esclerose múltipla (ms)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1018519.7A GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
GB201018519D0 GB201018519D0 (en) 2010-12-15
GB2485169A true GB2485169A (en) 2012-05-09

Family

ID=43401688

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1018519.7A Withdrawn GB2485169A (en) 2010-11-03 2010-11-03 (R)-flurbiprofen for use in the treatment of multiple sclerosis

Country Status (10)

Country Link
US (1) US20130309199A1 (cg-RX-API-DMAC10.html)
EP (1) EP2635271A1 (cg-RX-API-DMAC10.html)
JP (1) JP5903438B2 (cg-RX-API-DMAC10.html)
KR (1) KR101877587B1 (cg-RX-API-DMAC10.html)
CN (1) CN103209692A (cg-RX-API-DMAC10.html)
BR (1) BR112013010883A2 (cg-RX-API-DMAC10.html)
CA (1) CA2816911C (cg-RX-API-DMAC10.html)
GB (1) GB2485169A (cg-RX-API-DMAC10.html)
RU (1) RU2595861C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012059541A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017080989A1 (en) 2015-11-09 2017-05-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (r)-fluriprofen for the prevention and/or treatment of diabetes
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
AU2018368332B2 (en) 2017-11-14 2022-05-12 Merck Sharp & Dohme Llc Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2022089598A1 (zh) * 2020-10-30 2022-05-05 杭州拉林智能科技有限公司 黄酮苷-有机胺类神经激动剂复盐化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
MX2010006608A (es) * 2007-12-21 2010-10-05 Paz Arzneimittelentwicklung Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor.
KR20130079353A (ko) * 2010-04-21 2013-07-10 키에시 파르마슈티시 엣스. 피. 에이. 트랜스티레틴 아밀로이드증 치료용 1-(2-플루오로비페닐-4-일)-알킬 카복실산 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036733A2 (en) * 2006-09-19 2008-03-27 Myriad Genetics, Inc. Methods for treatment of vesicle transport disorders
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035792B1 (ru) * 2018-06-21 2020-08-11 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Лекарственное средство пролонгированного действия для лечения рассеянного склероза (варианты)

Also Published As

Publication number Publication date
JP2014505015A (ja) 2014-02-27
KR101877587B1 (ko) 2018-07-11
RU2013125470A (ru) 2014-12-10
RU2595861C2 (ru) 2016-08-27
GB201018519D0 (en) 2010-12-15
CA2816911C (en) 2018-09-25
US20130309199A1 (en) 2013-11-21
KR20140017494A (ko) 2014-02-11
CA2816911A1 (en) 2012-05-10
WO2012059541A1 (en) 2012-05-10
CN103209692A (zh) 2013-07-17
EP2635271A1 (en) 2013-09-11
BR112013010883A2 (pt) 2016-09-13
JP5903438B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
CA2816911C (en) Novel treatment of multiple sclerosis (ms)
EP2943222B1 (en) Solid solution compositions and use in severe pain
JP6139743B2 (ja) ロキソプロフェン含有医薬組成物
US20210161874A1 (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
JP2004269528A (ja) ヘルペスウイルス感染により引き起こされる疼痛又は炎症の緩和に有効な局所皮膚適用製剤
JPH07507057A (ja) 解熱鎮痛方法および光学的に純粋なｒ（‐）ケトプロフェンを含有する組成物
CN108349867A (zh) 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
JP2011506505A (ja) 痛みを伴う神経障害の治療の際の、医薬並びにその製造方法及び使用
KR102725563B1 (ko) 인돌 화합물을 사용한 통증 또는 간질성 방광염의 치료 방법
GB2493914A (en) Flurbiprofen and related compounds for the treatment of skin diseases
Driessen Pain: systemic and local/regional drug therapy
JPH07504410A (ja) （ｒ）−２−（３−ベンゾイルフェニル）プロピオン酸を含有する鎮痛剤として有用な薬学的組成物
CN104352488A (zh) 一类取代杂环衍生物在制备治疗疼痛药物中的应用
WO2021066136A1 (ja) 筋ジストロフィー治療薬
JP6811172B2 (ja) 抗痙攣化合物
MX388067B (es) Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico
JP2004331660A (ja) 医薬組成物
JP4444721B2 (ja) 医薬組成物
Jeong et al. The Effect of Mirogabalin on the Treatment of Intractable Postherpetic Neuralgia Not Responding Appropriately to Pregabalin: A Case Report
EP4098254A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
US20230002368A1 (en) Use of compounds for the prevention and/or treatment of ankylosing spondylitis, and corresponding compositions
CN1444942A (zh) 偏头痛治疗药
RU2575775C2 (ru) Фармацевтическая комбинация и ее применение
HK40018887A (en) Solid solution compositions and use in chronic inflammation
HK40049577B (en) Indole compound for treating interstitial cystitis

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20131031 AND 20131106

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)